Today, Intellia announced that the first patient has been treated with NTLA-2001, which we are developing as a potential single-course, curative therapy for all forms of #ATTR using #CRISPR /Cas9. Full press release here: https://t.co/Xc7gdW2nHo #transthyretinamyloidosis https://t.co/wjFELj45vg